Among patients with locally advanced or metastatic HER2-positive BC not amenable to curative surgery and/or radiation therapy, the median PFS was 4.5 months for the neratinib group and 6.8 months for the lapatinib plus capecitabine group (P = 0.231), and the OS was 19.7 and 23.6 months (P = 0.280), respectively(Martin et al. 2013). Here, ERBB2 is linked to breast cancer.